Cohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADC
Cohance Lifesciences is investing $18 million to increase its stake in NJ Bio and acquire a controlling interest in Aruka Bio. These moves are designed to consolidate the company's position in the antibody-drug conjugate (ADC) market.
Why it matters
Strategic consolidation in the biotech sector highlights the growing commercial importance of ADC technology in cancer treatment development.
Contract research, development and manufacturing organisation Cohance Lifesciences, formerly Suven Pharmaceuticals, is strengthening its antibody-drug conjugate (ADC) strategy with fresh investments in two biotechnology companies. It is investing an additional $13 million in NJ Bio and making a controlling investment of $5 million in Aruka Bio, expanding its capabilities and presence in the growing ADC segment.
The investments will aid in deeper integration of NJ Bio’s customer-facing services and focused development of Aruka’s proprietary pipeline through potential partnerships. Both the transactions will be funded through internal accruals, Cohance said on Thursday (September 3, 2026).
The company will increase its common-equity ownership in NJ Bio from 56% to 67.3%, acquiring the entire holdings of Priyashri Nayak and the Jain Family Irrevocable Trust. Dr. Naresh Jain will retain the remaining 32.7% and continue to lead NJ Bio while also advancing Aruka’s pipeline and partnership initiatives.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in